Aardvark Therapeutics (AARD) Research & Development (2024 - 2026)
Aardvark Therapeutics (AARD) posted Research & Development of $16.6 million for Q1 2026, up 15.86% sequentially from $14.3 million in Q4 2025, and up 113.63% YoY from $7.8 million in Q1 2025.
Aardvark Therapeutics (AARD) Research & Development (2024 - 2026) Analysis & Trends
Aardvark Therapeutics has reported Research & Development for 3 years, with the latest figure at $16.6 million in Q1 2026.
- Quarterly Research & Development rose 113.63% year-over-year to $16.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.7 million (up 141.51% YoY) and the FY2025 annual result came in at $48.9 million, up 181.84% from the prior year.
- Research & Development improved to $16.6 million in Q1 2026 per AARD's latest filing, from $14.3 million in the prior quarter.
- Over five years, Research & Development peaked at $16.6 million in Q1 2026 and troughed at $1.2 million in Q1 2024.
- A 3-year average of $9.2 million and a median of $8.1 million in 2024 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 542.5% in 2025, down 77.36% in 2025.
- Over 3 years, Research & Development stood at $8.1 million in 2024, then soared by 77.36% to $14.3 million in 2025, then rose by 15.86% to $16.6 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $16.6 million, $14.3 million, and $13.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Aardvark Therapeutics | 127.36 Mn | 53.44 Mn | - | 10.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.46 Mn |
| Mar 31, 2026 | 16.57 Mn |
| Dec 31, 2025 | 14.30 Mn |
| Sep 30, 2025 | 13.74 Mn |
| Jun 30, 2025 | 13.15 Mn |
| Mar 31, 2025 | 7.76 Mn |
| Dec 31, 2024 | 8.06 Mn |
| Sep 30, 2024 | 4.07 Mn |
| Jun 30, 2024 | 4.03 Mn |
| Mar 31, 2024 | 1.21 Mn |